EA201890146A1 - СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ - Google Patents
СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦInfo
- Publication number
- EA201890146A1 EA201890146A1 EA201890146A EA201890146A EA201890146A1 EA 201890146 A1 EA201890146 A1 EA 201890146A1 EA 201890146 A EA201890146 A EA 201890146A EA 201890146 A EA201890146 A EA 201890146A EA 201890146 A1 EA201890146 A1 EA 201890146A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- nanoparticles
- mtor inhibitor
- treatment
- solid tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Настоящее изобретение относится к способам и композициям для лечения солидной опухоли посредством введения композиций, содержащих наночастицы, которые содержат ингибитор mTOR (такой как лекарственное средство семейства "лимусов", например сиролимус или его производное) и альбумин, в комбинации с композициями, содержащими второе терапевтическое средство.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186325P | 2015-06-29 | 2015-06-29 | |
PCT/US2016/040202 WO2017004267A1 (en) | 2015-06-29 | 2016-06-29 | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201890146A1 true EA201890146A1 (ru) | 2018-06-29 |
Family
ID=57609103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890146A EA201890146A1 (ru) | 2015-06-29 | 2016-06-29 | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ |
Country Status (14)
Country | Link |
---|---|
US (2) | US20180153863A1 (ru) |
EP (1) | EP3313382A4 (ru) |
JP (1) | JP2018521058A (ru) |
KR (1) | KR20180019229A (ru) |
CN (1) | CN107921006A (ru) |
AU (1) | AU2016287508B2 (ru) |
CA (1) | CA2990726A1 (ru) |
CL (1) | CL2017003457A1 (ru) |
EA (1) | EA201890146A1 (ru) |
HK (1) | HK1247093A1 (ru) |
IL (1) | IL256333B2 (ru) |
MX (1) | MX2017016492A (ru) |
NZ (1) | NZ738929A (ru) |
WO (1) | WO2017004267A1 (ru) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2117520T (lt) | 2006-12-14 | 2018-12-10 | Abraxis Bioscience, Llc | Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną |
US20100297243A1 (en) | 2009-04-15 | 2010-11-25 | Desai Neil P | Prion free nanoparticle compositions and methods of making thereof |
KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
MX354216B (es) | 2011-04-28 | 2018-02-19 | Mercator Medsystems Inc | Suministro intravascular de composiciones de nanoparticulas y sus usos. |
RS59322B1 (sr) | 2011-12-14 | 2019-10-31 | Abraxis Bioscience Llc | Upotreba polimernih ekscipijenata za liofilizaciju ili zamrzavanje partikula |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
US10744110B2 (en) | 2013-03-12 | 2020-08-18 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
ES2904505T3 (es) * | 2015-01-12 | 2022-04-05 | Emcure Pharmaceuticals Ltd | Formulación líquida de cabazitaxel |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
KR20230165356A (ko) | 2015-06-29 | 2023-12-05 | 아브락시스 바이오사이언스, 엘엘씨 | 상피양 세포 종양을 치료하는 방법 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
US10841364B2 (en) * | 2017-03-27 | 2020-11-17 | International Business Machines Corporation | Using and comparing known and current activity states to determine receptiveness |
BR112019027402A2 (pt) * | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
WO2019126223A1 (en) * | 2017-12-19 | 2019-06-27 | Abraxis Bioscience, Llc | Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy |
CA3094453A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
AU2019237257A1 (en) * | 2018-03-23 | 2020-10-15 | ISR Immune System Regulation Holding AB (publ) | Combinations of macrolide compounds and immune checkpoint inhibitors |
SG11202011462SA (en) * | 2018-05-22 | 2020-12-30 | Abraxis Bioscience Llc | Methods and compositions for treating pulmonary hypertension |
US10350226B1 (en) * | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
WO2020123481A1 (en) * | 2018-12-10 | 2020-06-18 | Celator Pharmaceuticals Inc. | Combination formulations of taxanes and mtor inhibitors |
AU2020241730A1 (en) * | 2019-03-19 | 2021-10-28 | Abraxis Bioscience, Llc | Subcutaneous administration of nanoparticles comprising an mTOR inhibitor and albumin for treatment of diseases |
CN110055331B (zh) * | 2019-05-10 | 2023-05-02 | 人和未来生物科技(长沙)有限公司 | 一种用于膀胱癌辅助诊断或筛查的试剂盒及其应用 |
WO2020264181A1 (en) * | 2019-06-28 | 2020-12-30 | The Board Of Regents Of The University Of Oklahoma | Therapeutic annexin-drug conjugates and methods of use |
AU2020375810A1 (en) | 2019-10-28 | 2022-05-12 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
CN117045800A (zh) * | 2022-05-06 | 2023-11-14 | 上海科技大学 | mTOR抑制剂增强靶向蛋白降解药物功效的应用 |
WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101415409B (zh) * | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
AU2013204187B2 (en) * | 2007-03-07 | 2015-10-01 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
DK2481409T3 (en) * | 2007-03-07 | 2018-08-06 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
SG11201507234UA (en) * | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
JP6389241B2 (ja) * | 2013-04-17 | 2018-09-12 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのTORキナーゼ阻害剤及びIMiD化合物を含む組合せ療法 |
-
2016
- 2016-06-29 AU AU2016287508A patent/AU2016287508B2/en active Active
- 2016-06-29 JP JP2017568137A patent/JP2018521058A/ja active Pending
- 2016-06-29 KR KR1020187002291A patent/KR20180019229A/ko not_active Application Discontinuation
- 2016-06-29 WO PCT/US2016/040202 patent/WO2017004267A1/en active Application Filing
- 2016-06-29 US US15/737,943 patent/US20180153863A1/en not_active Abandoned
- 2016-06-29 NZ NZ738929A patent/NZ738929A/en unknown
- 2016-06-29 CA CA2990726A patent/CA2990726A1/en not_active Abandoned
- 2016-06-29 EP EP16818728.4A patent/EP3313382A4/en active Pending
- 2016-06-29 EA EA201890146A patent/EA201890146A1/ru unknown
- 2016-06-29 MX MX2017016492A patent/MX2017016492A/es unknown
- 2016-06-29 CN CN201680049598.0A patent/CN107921006A/zh active Pending
-
2017
- 2017-12-14 IL IL256333A patent/IL256333B2/en unknown
- 2017-12-28 CL CL2017003457A patent/CL2017003457A1/es unknown
-
2018
- 2018-05-21 HK HK18106582.1A patent/HK1247093A1/zh unknown
-
2022
- 2022-06-27 US US17/850,806 patent/US20230263779A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180153863A1 (en) | 2018-06-07 |
EP3313382A4 (en) | 2019-03-06 |
MX2017016492A (es) | 2018-08-16 |
AU2016287508B2 (en) | 2021-10-14 |
NZ738929A (en) | 2024-01-26 |
IL256333A (en) | 2018-02-28 |
KR20180019229A (ko) | 2018-02-23 |
CN107921006A (zh) | 2018-04-17 |
CL2017003457A1 (es) | 2018-05-11 |
IL256333B (en) | 2022-11-01 |
JP2018521058A (ja) | 2018-08-02 |
IL256333B2 (en) | 2023-03-01 |
US20230263779A1 (en) | 2023-08-24 |
HK1247093A1 (zh) | 2018-09-21 |
AU2016287508A1 (en) | 2018-02-01 |
CA2990726A1 (en) | 2017-01-05 |
WO2017004267A1 (en) | 2017-01-05 |
EP3313382A1 (en) | 2018-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
EA201890159A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
NZ729643A (en) | Combination therapy for treating cancer | |
EA202091514A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
WO2016133903A3 (en) | Combination therapy for cancer treatment | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
PH12016502353A1 (en) | Pharmaceutical composition | |
EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
MX2019003694A (es) | Metodos para tratar cancer del tracto biliar. | |
EA201691570A1 (ru) | Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
PH12020500666A1 (en) | Pladienolide compounds and their use | |
EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist |